Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6386269 | 0.74 | HTR2A (0.50) | CYP19A1IDO1CYP2D6 | |
| SCHEMBL4230463 | 0.74 | CYP2D6 (0.45) | TYMSCYP11B2HTR1ASLC6A2SLC6A4 | |
| SCHEMBL6385324 | 0.74 | CYP19A1 (0.40) | DRD2DRD3CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL5941266 | 0.72 | ANPEP (0.42) | CYP19A1CYP2D6 | |
| SCHEMBL6385408 | 0.71 | MAPK14 (0.47) | TYMSCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6387841 | 0.71 | CYP19A1 (0.40) | TYMSCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL6387839 | 0.71 | CYP19A1 (0.40) | TYMSCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL1266396 | 0.66 | CYP19A1 (0.43) | DRD2DRD3CYP19A1CYP2D6 | |
| SCHEMBL14578648 | 0.66 | CYP19A1 (0.43) | DRD2DRD3CYP19A1CYP2D6 | |
| SCHEMBL1150855 | 0.66 | DRD2 (0.53) | DRD2DRD3CYP11B1CYP11B2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051276-A2 | THERAPEUTIC HETEROCYCLES | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099195-A1 | Therapeutic Compounds 570 | OPRL1, OPRK1, OPRM1 | TYMS 1072/4885DRD2 2300/4885DRD3 1711/4885 |
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | TYMS 684/4885DRD2 873/4885DRD3 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.